Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors.

Background: Currently, the goal of chronic myeloid leukemia (CML) treatment is normal survival and good quality of life without life-long treatment, namely, "treatment-free remission" (TFR). At present, approximately only 50% of patients with CML with a deep molecular response are able to discontinue tyrosine kinase inhibitor (TKI) without experiencing molecular relapse [MR; loss of major molecular response (MMR)]. In addition, prior interferon (IFN) treatment is associated with a higher rate of TFR.

Discriminating clinical phases of recovery from major depressive disorder using the dynamics of facial expression.

We used several metrics of variability to extract unsupervised features from video recordings of patients before and after deep brain stimulation (DBS) treatment for major depressive disorder (MDD). Our goal was to quantify the treatment effects on facial expressivity. Multiscale entropy (MSE) was used to capture the temporal variability in pixel intensity level at multiple time-scales.